Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic ...

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

Add Yahoo as a preferred source to see more of our stories on Google. WASHINGTON (DC News Now) — September is Prostate Cancer Awareness Month, and according to the National Cancer Institute (NCI), ...

Non-Muscle Invasive Bladder Cancer Market · GlobeNewswire Inc. The non-muscle invasive bladder cancer (NMIBC) market size has experienced robust growth, increasing from $3.66 billion in 2025 to an ...

Since many cancers don’t have symptoms early on, they may go unnoticed until they are at an advanced stage. But that is ...

SAN FRANCISCO, May 22, 2025 /PRNewswire/ -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...

The Shield Across America Tour is in Nashville offering a non-invasive, FDA-approved blood test for colorectal cancer ...